Standout Papers

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, ... 2016 2026 2019 2022 828
  1. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial (2016)
    Kei Muro, Hyun Cheol Chung et al. The Lancet Oncology
  2. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer (2017)
    Jennifer H. Yearley, Christopher J. Gibson et al. Clinical Cancer Research
  3. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer (2018)
    Karina Kulangara, Nancy R. Zhang et al. Archives of Pathology & Laboratory Medicine

Immediate Impact

1 by Nobel laureates 14 from Science/Nature 62 standout
Sub-graph 1 of 17

Citing Papers

The dawn of spatial omics
2023 StandoutScience
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
2023 Standout
1 intermediate paper

Works of Jonathan Juco being referenced

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
2018 Standout
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Jonathan Juco 1848 1007 368 725 23 2.5k
Kumudu Pathiraja 2593 1119 290 564 36 3.3k
Marina Tschaika 1617 661 212 653 37 2.2k
Robert Ford 2090 1387 255 593 19 3.6k
Christian Meyer zum Büschenfelde 1385 1031 154 719 31 2.4k
J.H.J.M. van Krieken 1511 1312 466 1005 34 3.4k
Joseph L. Leach 1998 562 818 723 38 2.8k
Tianhua Guo 910 1551 210 525 14 2.7k
Akin Atmaca 2103 1380 195 553 60 3.2k
Gregg Fine 2744 885 426 802 32 3.7k
Bryan Goldman 1257 1631 307 953 64 3.4k

All Works

Loading papers...

Rankless by CCL
2026